Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose. This is an ASCO Meeting Abstract ...
Although existing studies of unpaired samples demonstrate test success and almost identical median RS results, 29, 38 a direct comparison of RS results on paired samples from the same tumor, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results